Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia-MedSci.cn

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia

Zhang, X; Qian, JJ; Wang, HF; Wang, YG; Zhang, Y; Qian, PX; Lou, YJ; Jin, J; Zhu, HH

Zhu, HH (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Sch Med, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.; Zhu, HH (corresponding author), Key Lab Hematol Malignancies Diag & Treatment, Hangzhou, Zhejiang, Peoples R China.

Abstract

Y Venetoclax (VEN) plus azacitidine has become the first-line therapy for elderly patients with acute myeloid leukemia (AML), and has a complete remis......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia

科室

工具

服务